Methenolone (also known as primobolan) was described in 1960. Squibb Company began producing injectable drug in 1962. Methenolone originally was prescribed in case of muscle loss after operations, infections, long-term illnesses, aggressive therapy with corticoids or malnutrition, and in some cases it was used to treat osteoporosis and breast cancer.
Methenolone belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. Thus, methenolone is considered to be a steroid lipid molecule. Methenolone is considered to be a practically insoluble (in water) and relatively neutral molecule. Methenolone has been found in human hepatic tissue tissue, and has also been primarily detected in urine. Within the cell, methenolone is primarily located in the membrane (predicted from logP) and cytoplasm.